JP2010523680A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010523680A5 JP2010523680A5 JP2010503084A JP2010503084A JP2010523680A5 JP 2010523680 A5 JP2010523680 A5 JP 2010523680A5 JP 2010503084 A JP2010503084 A JP 2010503084A JP 2010503084 A JP2010503084 A JP 2010503084A JP 2010523680 A5 JP2010523680 A5 JP 2010523680A5
- Authority
- JP
- Japan
- Prior art keywords
- erbb
- met
- agent
- therapeutic
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 133
- 229940124597 therapeutic agent Drugs 0.000 claims 71
- 239000003795 chemical substances by application Substances 0.000 claims 65
- 206010028980 Neoplasm Diseases 0.000 claims 42
- 201000011510 cancer Diseases 0.000 claims 42
- 210000004027 cell Anatomy 0.000 claims 41
- 230000004544 DNA amplification Effects 0.000 claims 33
- 230000035772 mutation Effects 0.000 claims 32
- 230000001225 therapeutic effect Effects 0.000 claims 27
- 101150105382 MET gene Proteins 0.000 claims 20
- 230000003213 activating effect Effects 0.000 claims 19
- 229940079593 drug Drugs 0.000 claims 17
- 230000004913 activation Effects 0.000 claims 16
- 238000011282 treatment Methods 0.000 claims 14
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 12
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 12
- 238000000034 method Methods 0.000 claims 10
- 230000001404 mediated effect Effects 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 6
- 150000003384 small molecules Chemical class 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 5
- 230000026731 phosphorylation Effects 0.000 claims 5
- 238000006366 phosphorylation reaction Methods 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 229960005395 cetuximab Drugs 0.000 claims 4
- 229960000575 trastuzumab Drugs 0.000 claims 4
- 101150039808 Egfr gene Proteins 0.000 claims 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 3
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 3
- -1 PF00299804 Chemical compound 0.000 claims 3
- 108020004459 Small interfering RNA Proteins 0.000 claims 3
- 229960001686 afatinib Drugs 0.000 claims 3
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 3
- 229950002826 canertinib Drugs 0.000 claims 3
- OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 108700021358 erbB-1 Genes Proteins 0.000 claims 3
- 229960001433 erlotinib Drugs 0.000 claims 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 3
- 229960002584 gefitinib Drugs 0.000 claims 3
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 229960004891 lapatinib Drugs 0.000 claims 3
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 3
- ZAJXXUDARPGGOC-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-[3-methyl-3-(4-methylpiperazin-1-yl)but-1-ynyl]quinazolin-6-yl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C)(C)C#CC1=CC2=NC=NC(NC=3C=C(Cl)C(F)=CC=3)=C2C=C1NC(=O)C=C ZAJXXUDARPGGOC-UHFFFAOYSA-N 0.000 claims 3
- 229950008835 neratinib Drugs 0.000 claims 3
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 3
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 claims 3
- HVXKQKFEHMGHSL-QKDCVEJESA-N tesevatinib Chemical compound N1=CN=C2C=C(OC[C@@H]3C[C@@H]4CN(C)C[C@@H]4C3)C(OC)=CC2=C1NC1=CC=C(Cl)C(Cl)=C1F HVXKQKFEHMGHSL-QKDCVEJESA-N 0.000 claims 3
- 229960000241 vandetanib Drugs 0.000 claims 3
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010064571 Gene mutation Diseases 0.000 claims 2
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims 2
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- BCZUAADEACICHN-UHFFFAOYSA-N SGX-523 Chemical compound C1=NN(C)C=C1C1=NN2C(SC=3C=C4C=CC=NC4=CC=3)=NN=C2C=C1 BCZUAADEACICHN-UHFFFAOYSA-N 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 229960001292 cabozantinib Drugs 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 229960005061 crizotinib Drugs 0.000 claims 2
- 229940121647 egfr inhibitor Drugs 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 229950007540 glesatinib Drugs 0.000 claims 2
- 230000012010 growth Effects 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 238000002430 laser surgery Methods 0.000 claims 2
- 238000002647 laser therapy Methods 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- YRCHYHRCBXNYNU-UHFFFAOYSA-N n-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=S)NC(=O)CC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 YRCHYHRCBXNYNU-UHFFFAOYSA-N 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 238000002428 photodynamic therapy Methods 0.000 claims 2
- 229950003647 semaxanib Drugs 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 229950005976 tivantinib Drugs 0.000 claims 2
- 238000011277 treatment modality Methods 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 101150022655 HGF gene Proteins 0.000 claims 1
- 102000038030 PI3Ks Human genes 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000033077 cellular process Effects 0.000 claims 1
- 230000008859 change Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 230000008569 process Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000000523 sample Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92338407P | 2007-04-13 | 2007-04-13 | |
| US60/923,384 | 2007-04-13 | ||
| PCT/US2008/004804 WO2008127710A2 (en) | 2007-04-13 | 2008-04-11 | Methods for treating cancer resistant to erbb therapeutics |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014097474A Division JP2014141530A (ja) | 2007-04-13 | 2014-05-09 | ＥｒｂＢ療法に耐性である癌を治療するための方法 |
| JP2016039191A Division JP2016121176A (ja) | 2007-04-13 | 2016-03-01 | ＥｒｂＢ療法に耐性である癌を治療するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010523680A JP2010523680A (ja) | 2010-07-15 |
| JP2010523680A5 true JP2010523680A5 (https=) | 2011-11-04 |
| JP5926487B2 JP5926487B2 (ja) | 2016-05-25 |
Family
ID=39561970
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010503084A Active JP5926487B2 (ja) | 2007-04-13 | 2008-04-11 | ＥｒｂＢ療法に耐性である癌を治療するための方法 |
| JP2014097474A Pending JP2014141530A (ja) | 2007-04-13 | 2014-05-09 | ＥｒｂＢ療法に耐性である癌を治療するための方法 |
| JP2016039191A Withdrawn JP2016121176A (ja) | 2007-04-13 | 2016-03-01 | ＥｒｂＢ療法に耐性である癌を治療するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014097474A Pending JP2014141530A (ja) | 2007-04-13 | 2014-05-09 | ＥｒｂＢ療法に耐性である癌を治療するための方法 |
| JP2016039191A Withdrawn JP2016121176A (ja) | 2007-04-13 | 2016-03-01 | ＥｒｂＢ療法に耐性である癌を治療するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US8715665B2 (https=) |
| EP (2) | EP2076289B1 (https=) |
| JP (3) | JP5926487B2 (https=) |
| AU (1) | AU2008239594B2 (https=) |
| CA (1) | CA2683559C (https=) |
| DK (1) | DK2076289T3 (https=) |
| ES (1) | ES2529790T3 (https=) |
| WO (1) | WO2008127710A2 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101313702B1 (ko) | 2005-02-03 | 2013-10-04 | 와이어쓰 | 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물 |
| EP1942937A1 (en) | 2005-11-04 | 2008-07-16 | Wyeth | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| AU2008239594B2 (en) * | 2007-04-13 | 2013-10-24 | Beth Israel Deaconess Medical Center | Methods for treating cancer resistant to ErbB therapeutics |
| US20090042906A1 (en) * | 2007-04-26 | 2009-02-12 | Massachusetts Institute Of Technology | Methods for treating cancers associated with constitutive egfr signaling |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| KR20100135780A (ko) * | 2008-03-06 | 2010-12-27 | 제넨테크, 인크. | Ｃ-ｍｅｔ 및 ｅｇｆｒ 길항제로의 조합 요법 |
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| BRPI0914790A2 (pt) | 2008-06-17 | 2015-10-20 | Wyeth Llc | uso de um composto de vinorelbina e um composto de hki-272, composição farmacêutica e produto e kit para o tratamento de neoplasma |
| US8669273B2 (en) | 2008-08-04 | 2014-03-11 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| WO2010019952A2 (en) * | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
| US20110135651A1 (en) * | 2008-08-19 | 2011-06-09 | Children's Hospital Medical Center | Method and composition for enhancing hematopoietic stem cell mobilization |
| JP2012504606A (ja) * | 2008-10-01 | 2012-02-23 | ラディック インスティテュート フォー キャンサー リサーチ | 癌の治療方法 |
| TWI460178B (zh) | 2009-02-12 | 2014-11-11 | Arqule Inc | 組合性組成物及治療癌症之方法 |
| DK3000467T3 (da) | 2009-04-06 | 2023-03-27 | Wyeth Llc | Behandling med neratinib mod brystkræft |
| AU2015201262B2 (en) * | 2009-11-13 | 2017-04-27 | Amgen Inc. | Material and methods for treating or preventing her-3 associated diseases |
| CA2783743C (en) * | 2009-12-11 | 2022-10-04 | Wyeth Llc | Phosphatidylinositol-3-kinase pathway biomarkers |
| KR101798679B1 (ko) | 2010-03-11 | 2017-11-16 | 메리맥 파마슈티컬즈, 인크. | ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도 |
| EP2576621B1 (en) | 2010-05-27 | 2019-04-10 | Genmab A/S | Monoclonal antibodies against her2 |
| CA2800769C (en) | 2010-05-27 | 2021-11-02 | Genmab A/S | Monoclonal antibodies against her2 epitope |
| US20110301194A1 (en) * | 2010-06-02 | 2011-12-08 | Arqule, Inc. | Method for Determining Treatment Efficacy |
| US8580764B2 (en) | 2010-07-01 | 2013-11-12 | Arqule, Inc. | Combinational compositions and methods for treatment of cancer |
| EP2611443A2 (en) * | 2010-09-01 | 2013-07-10 | ArQule, Inc. | Methods for treatment of non-small cell lung cancer |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| SG191230A1 (en) * | 2010-12-23 | 2013-07-31 | Nestec Sa | Drug selection for malignant cancer therapy using antibody-based arrays |
| AU2012245116A1 (en) | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
| DK2797957T3 (da) | 2011-11-23 | 2019-09-23 | Medimmune Llc | Bindingsmolekyler specifikke for her3 og anvendelser deraf |
| JP2015512447A (ja) * | 2012-04-03 | 2015-04-27 | ノバルティス アーゲー | チロシンキナーゼ阻害薬の組合せおよびその使用 |
| US20170275367A1 (en) | 2012-11-21 | 2017-09-28 | Janssen Biotech, Inc. | Bispecific EGFR/C-Met Antibodies |
| MX361088B (es) | 2012-11-21 | 2018-11-26 | Janssen Biotech Inc | Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos. |
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| CN105264084A (zh) | 2013-01-14 | 2016-01-20 | 中央研究院 | 静默egfr表达的脱氧核糖核酸酶 |
| WO2014182521A1 (en) * | 2013-05-06 | 2014-11-13 | Medimmune, Llc | Diagnostic methods and treatments for cancer |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| BR112016008125B1 (pt) | 2013-10-14 | 2023-11-21 | Janssen Biotech, Inc. | Domínio proteico isolado de fibronectina tipo iii modificado com cisteína, seu método de produção e método para produzir uma molécula isolada de de fibronectina tipo iii biespecífica modificada com cisteína |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
| WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
| KR101751371B1 (ko) * | 2014-06-25 | 2017-06-27 | 연세대학교 원주산학협력단 | 3,4,5-트리하이드록시벤조산, 이의 유도체 또는 이의 염을 유효성분으로 포함하는 수용체 티로신 키나아제 저해제 내성 항암제 조성물 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| BR112018002550A2 (en) | 2015-08-10 | 2018-09-18 | Dana-Farber Cancer Institute, Inc. | inhibitor resistance mechanism |
| WO2017201156A1 (en) * | 2016-05-18 | 2017-11-23 | Duke University | Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab |
| MA45412A (fr) | 2016-06-21 | 2021-05-26 | Janssen Biotech Inc | Molécules de liaison au domaine de fibronectine de type iii modifiées par la cystéine |
| EP3554535A4 (en) | 2016-12-14 | 2020-10-21 | Janssen Biotech, Inc. | PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS |
| EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| CN110225770B (zh) | 2016-12-14 | 2022-04-26 | 杨森生物科技公司 | 结合cd8a的纤连蛋白iii型结构域 |
| WO2019178239A1 (en) * | 2018-03-13 | 2019-09-19 | Board Of Regents, The University Of Texas System | Methods for treatment of cancers with egfr activating mutations |
| BR112021016149A2 (pt) | 2019-02-26 | 2021-10-13 | Janssen Biotech, Inc. | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| WO2021076543A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| CN119119240A (zh) | 2019-10-14 | 2024-12-13 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| JP7783182B2 (ja) | 2020-02-12 | 2025-12-09 | ヤンセン バイオテツク，インコーポレーテツド | ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療 |
| EP4323008A4 (en) | 2021-04-14 | 2026-02-25 | Aro Biotherapeutics Company | FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES |
| CA3214552A1 (en) | 2021-04-14 | 2022-10-20 | Russell C. Addis | Cd71 binding fibronectin type iii domains |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3654090A (en) | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4683203A (en) | 1984-04-14 | 1987-07-28 | Redco N.V. | Immobilized enzymes, processes for preparing same, and use thereof |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4716432A (en) | 1986-04-24 | 1987-12-29 | Eastman Kodak Company | Exposure control apparatus |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| IL86724A (en) | 1987-06-19 | 1995-01-24 | Siska Diagnostics Inc | Methods and kits for amplification and testing of nucleic acid sequences |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5556750A (en) | 1989-05-12 | 1996-09-17 | Duke University | Methods and kits for fractionating a population of DNA molecules based on the presence or absence of a base-pair mismatch utilizing mismatch repair systems |
| US5459039A (en) | 1989-05-12 | 1995-10-17 | Duke University | Methods for mapping genetic mutations |
| US6008031A (en) | 1989-05-12 | 1999-12-28 | Duke University | Method of analysis and manipulation of DNA utilizing mismatch repair systems |
| US5242974A (en) | 1991-11-22 | 1993-09-07 | Affymax Technologies N.V. | Polymer reversal on solid surfaces |
| US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
| US6551784B2 (en) | 1989-06-07 | 2003-04-22 | Affymetrix Inc | Method of comparing nucleic acid sequences |
| US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5252743A (en) | 1989-11-13 | 1993-10-12 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
| AU647741B2 (en) | 1989-12-01 | 1994-03-31 | Regents Of The University Of California, The | Methods and compositions for chromosome-specific staining |
| DE69132531T2 (de) | 1990-12-06 | 2001-09-13 | Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) | Verbindungen und ihre Verwendung in einer binären Synthesestrategie |
| US5639603A (en) | 1991-09-18 | 1997-06-17 | Affymax Technologies N.V. | Synthesizing and screening molecular diversity |
| US5770358A (en) | 1991-09-18 | 1998-06-23 | Affymax Technologies N.V. | Tagged synthetic oligomer libraries |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| CA2124087C (en) | 1991-11-22 | 2002-10-01 | James L. Winkler | Combinatorial strategies for polymer synthesis |
| US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
| US5550215A (en) | 1991-11-22 | 1996-08-27 | Holmes; Christopher P. | Polymer reversal on solid surfaces |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5541061A (en) | 1992-04-29 | 1996-07-30 | Affymax Technologies N.V. | Methods for screening factorial chemical libraries |
| EP0642589A4 (en) | 1992-05-11 | 1997-05-21 | Ribozyme Pharm Inc | METHOD AND REAGENT TO INHIBIT VIRAL REPLICATION. |
| EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
| US5288514A (en) | 1992-09-14 | 1994-02-22 | The Regents Of The University Of California | Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support |
| US5491074A (en) | 1993-04-01 | 1996-02-13 | Affymax Technologies Nv | Association peptides |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
| US6090555A (en) | 1997-12-11 | 2000-07-18 | Affymetrix, Inc. | Scanned image alignment systems and methods |
| EP0758403B1 (en) | 1994-05-05 | 1998-06-24 | Beckman Instruments, Inc. | Oligonucleotide repeat arrays |
| US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
| US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
| US5599695A (en) | 1995-02-27 | 1997-02-04 | Affymetrix, Inc. | Printing molecular library arrays using deprotection agents solely in the vapor phase |
| US5624711A (en) | 1995-04-27 | 1997-04-29 | Affymax Technologies, N.V. | Derivatization of solid supports and methods for oligomer synthesis |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5968740A (en) | 1995-07-24 | 1999-10-19 | Affymetrix, Inc. | Method of Identifying a Base in a Nucleic Acid |
| GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
| WO1997021837A1 (en) | 1995-12-15 | 1997-06-19 | Amersham Life Science, Inc. | Methods for the detection and removal of mutant sequences that arise during enzymatic amplification using mismatch repair systems |
| DE69739909D1 (de) | 1996-03-26 | 2010-07-29 | Michael S Kopreski | Methoden aus plasma oder serum extrahierte extrazelluraere rna zur diagnoseüberwachung oder evaluation von krebs verwenden |
| EP0902885A4 (en) | 1996-05-16 | 2006-09-27 | Affymetrix Inc | SYSTEMS AND METHODS FOR DETECTION OF BRANDED PRODUCTS |
| US5869245A (en) | 1996-06-05 | 1999-02-09 | Fox Chase Cancer Center | Mismatch endonuclease and its use in identifying mutations in targeted polynucleotide strands |
| AR007857A1 (es) | 1996-07-13 | 1999-11-24 | Glaxo Group Ltd | Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen. |
| EA199900021A1 (ru) | 1996-07-13 | 1999-08-26 | Глаксо, Груп Лимитед | Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| WO1999004819A1 (en) | 1997-07-24 | 1999-02-04 | Inex Pharmaceuticals Corporation | Liposomal compositions for the delivery of nucleic acid catalysts |
| DE69829402T2 (de) | 1997-10-31 | 2006-04-13 | Affymetrix, Inc. (a Delaware Corp.), Santa Clara | Expressionsprofile in adulten und fötalen organen |
| US5976813A (en) | 1997-12-12 | 1999-11-02 | Abbott Laboratories | Continuous format high throughput screening |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| US6269846B1 (en) | 1998-01-13 | 2001-08-07 | Genetic Microsystems, Inc. | Depositing fluid specimens on substrates, resulting ordered arrays, techniques for deposition of arrays |
| US6428752B1 (en) | 1998-05-14 | 2002-08-06 | Affymetrix, Inc. | Cleaning deposit devices that form microarrays and the like |
| US6375903B1 (en) | 1998-02-23 | 2002-04-23 | Wisconsin Alumni Research Foundation | Method and apparatus for synthesis of arrays of DNA probes |
| US5936324A (en) | 1998-03-30 | 1999-08-10 | Genetic Microsystems Inc. | Moving magnet scanner |
| SK287132B6 (sk) | 1998-05-29 | 2009-12-07 | Sugen, Inc. | Farmaceutická kompozícia obsahujúca pyrolom substituovaný 2-indolinón, súprava obsahujúca uvedenú kompozíciu a použitie pyrolom substituovaného 2-indolinónu |
| UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
| US6197599B1 (en) | 1998-07-30 | 2001-03-06 | Guorong Chin | Method to detect proteins |
| DK1137941T4 (da) | 1998-12-10 | 2014-01-06 | Brystol Myers Squibb Company | Protein-scaffolds til antistof-mimetika og andre bindingsproteiner |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US6232068B1 (en) | 1999-01-22 | 2001-05-15 | Rosetta Inpharmatics, Inc. | Monitoring of gene expression by detecting hybridization to nucleic acid arrays using anti-heteronucleic acid antibodies |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| US6110462A (en) | 1999-03-03 | 2000-08-29 | The Scripps Research Institute | Enzymatic DNA molecules that contain modified nucleotides |
| JP2002539849A (ja) | 1999-03-26 | 2002-11-26 | ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ | ユニバーサルアレイ |
| AU2001253255A1 (en) | 2000-04-07 | 2001-10-23 | Large Scale Biology Corporation | Compositions and methods for inhibiting gene expression |
| EP1292591B1 (en) | 2000-06-22 | 2005-02-02 | Pfizer Products Inc. | Substituted bicyclic derivatives for the treatment of abnormal cell growth |
| EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
| ME00502B (me) | 2001-01-05 | 2011-10-10 | Amgen Fremont Inc | Antitjela za insulinu sličan receptor faktora i rasta |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| EP1444365A4 (en) | 2001-10-25 | 2005-07-20 | Gorilla Genomics Inc | ASYMMETRIC PCR WITH NUCLEASE-FREE POLYMERASE OR NUCLEASERESISTENT MOLECULAR BEACONS |
| US20040229294A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
| EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
| DK1603570T5 (da) | 2003-02-26 | 2013-12-09 | Sugen Inc | Aminoheteroarylforbindelser som proteinkinaseinhibitorer |
| EP3042964A1 (en) | 2004-06-04 | 2016-07-13 | Genentech, Inc. | Egfr mutations |
| DE602005020465D1 (de) * | 2004-08-26 | 2010-05-20 | Pfizer | Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer |
| ES2355923T3 (es) | 2004-08-26 | 2011-04-01 | Pfizer, Inc. | Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa. |
| US20060084691A1 (en) * | 2004-10-18 | 2006-04-20 | Bilal Piperdi | Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor |
| US7862995B2 (en) | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
| KR101313702B1 (ko) | 2005-02-03 | 2013-10-04 | 와이어쓰 | 제피티니브 및/또는 에를로티니브 내성암 치료용 약제학적 조성물 |
| KR20080003334A (ko) | 2005-03-11 | 2008-01-07 | 더 리젠트스 오브 더 유니버시티 오브 콜로라도 | 암 세포를 표피 성장 인자 억제제에 대해 감작화시키는히스톤 데아세틸라제 억제제 |
| US8652786B2 (en) * | 2005-04-05 | 2014-02-18 | The General Hospital Corporation | Method for predicting responsiveness to drugs |
| AR053272A1 (es) | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | Determinacion de responsivos a la quimioterapia |
| JP2008542354A (ja) | 2005-06-03 | 2008-11-27 | ファイザー・プロダクツ・インク | 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用 |
| UA95244C2 (ru) | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Соединения и способ модулирования активности киназ, и показания для их применения |
| WO2007015947A2 (en) | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies |
| GB0517387D0 (en) * | 2005-08-26 | 2005-10-05 | Antisoma Res Ltd | Combinations for the treatment of cancer |
| WO2007109571A2 (en) | 2006-03-17 | 2007-09-27 | Prometheus Laboratories, Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
| AU2008239594B2 (en) * | 2007-04-13 | 2013-10-24 | Beth Israel Deaconess Medical Center | Methods for treating cancer resistant to ErbB therapeutics |
| WO2008127707A1 (en) | 2007-04-13 | 2008-10-23 | Dana Farber Cancer Institute, Inc. | Receptor tyrosine kinase profiling |
| US8312249B1 (en) | 2008-10-10 | 2012-11-13 | Apple Inc. | Dynamic trampoline and structured code generation in a signed code environment |
-
2008
- 2008-04-11 AU AU2008239594A patent/AU2008239594B2/en active Active
- 2008-04-11 WO PCT/US2008/004804 patent/WO2008127710A2/en not_active Ceased
- 2008-04-11 DK DK08742861.1T patent/DK2076289T3/da active
- 2008-04-11 EP EP08742861.1A patent/EP2076289B1/en active Active
- 2008-04-11 CA CA2683559A patent/CA2683559C/en active Active
- 2008-04-11 ES ES08742861.1T patent/ES2529790T3/es active Active
- 2008-04-11 JP JP2010503084A patent/JP5926487B2/ja active Active
- 2008-04-11 EP EP14189064.0A patent/EP2851091B1/en active Active
- 2008-04-11 US US12/450,826 patent/US8715665B2/en active Active
-
2014
- 2014-04-18 US US14/256,418 patent/US20140296100A1/en not_active Abandoned
- 2014-05-09 JP JP2014097474A patent/JP2014141530A/ja active Pending
-
2015
- 2015-12-11 US US14/965,923 patent/US11008620B2/en active Active
-
2016
- 2016-03-01 JP JP2016039191A patent/JP2016121176A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010523680A5 (https=) | ||
| US20250333479A1 (en) | Novel fusion molecules and uses thereof | |
| He et al. | The G protein α subunit Gα s is a tumor suppressor in Sonic hedgehog− driven medulloblastoma | |
| JP5985401B2 (ja) | 第一の癌療法に対する耐性を現に有するか、または、そのような耐性を生じる患者において癌を診断および治療する方法 | |
| AU2020220205A1 (en) | TEC family kinase inhibitor adjuvant therapy | |
| RU2014151207A (ru) | Селективность в отношении мутантных форм и комбинации соединения, представляющего собой ингибитор фосфоинозитид-3-киназы, и химиотерапевтических агентов для лечения рака | |
| KR20190052062A (ko) | Raf 억제제 및 erk 억제제를 포함하는 치료적 조합 | |
| Fury et al. | A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer | |
| TW201414475A (zh) | 使用馬賽替尼治療以預測因子所識別的癌症患者亞群 | |
| Singh et al. | Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR-ErbB2 signaling with lapatinib | |
| Widemann et al. | CTF meeting 2012: translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies | |
| Shi et al. | Non-image-forming photoreceptors improve visual orientation selectivity and image perception | |
| US10792284B2 (en) | Synergistic cancer treatment | |
| JP7291987B2 (ja) | チロシンキナーゼ阻害剤と併用してｅｇｆ／ｅｇｆｒ経路を抑制する方法および組成物 | |
| WO2017117386A1 (en) | Methods of treating cancer using network brakes | |
| JP5579699B2 (ja) | 分子標的薬に対する感受性が低下している癌の治療薬および分子標的薬に対する感受性を増強する医薬組成物 | |
| CN115175678B (zh) | 使用btk抑制剂及其组合治疗dlbcl的方法 | |
| Xiang et al. | EID3 promotes glioma cell proliferation and survival by inactivating AMPKα1 | |
| US20260116962A1 (en) | Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer | |
| Hanson et al. | ETMR-06. PNOC031-international trial for embryonal tumor with multilayered rosettes | |
| ES2670596T3 (es) | Terapia de combinación para prevenir la formación del DCIS y la progresión hasta cáncer de mama | |
| Tian et al. | 1014P Resistance landscape to almonertinib in EGFR-mutated NSCLC | |
| García-Colomer et al. | Rapamycin can revert CCM phenotype in brain endothelial cells and ameliorates chronic cavernoma development in combination with lapatinib | |
| Stewart | Amivantamab plus Lazertinib Combination Shows Promise in Osimertinib-Resistant EGFR-Positive NSCLC. | |
| Bottone et al. | Brain Cancers: New Perspectives and Therapies |